VOTUBIA Tablet Ref.[113481] Active ingredients: Everolimus

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Product name and form

Votubia 2.5 mg tablets.

Votubia 5 mg tablets.

Votubia 10 mg tablets.

Pharmaceutical Form

Tablet.

Votubia 2.5 mg tablets: White to slightly yellow, elongated tablets of approximately 10.1 mm in length and 4.1 mm in width, with a bevelled edge and no score, engraved with “LCL” on one side and “NVR” on the other.

Votubia 5 mg tablets: White to slightly yellow, elongated tablets of approximately 12.1 mm in length and 4.9 mm in width, with a bevelled edge and no score, engraved with “5” on one side and “NVR” on the other.

Votubia 10 mg tablets: White to slightly yellow, elongated tablets of approximately 15.1 mm in length and 6.0 mm in width, with a bevelled edge and no score, engraved with “UHE” on one side and “NVR” on the other.

Qualitative and quantitative composition

Votubia 2.5 mg tablets

Each tablet contains 2.5 mg everolimus.

Excipient with known effect: Each tablet contains 74 mg lactose.

Votubia 5 mg tablets

Each tablet contains 5 mg everolimus.

Excipient with known effect: Each tablet contains 149 mg lactose.

Votubia 10 mg tablets

Each tablet contains 10 mg everolimus.

Excipient with known effect: Each tablet contains 297 mg lactose.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Everolimus

Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers.

List of Excipients

Butylated hydroxytoluene (E321)
Magnesium stearate
Lactose monohydrate
Hypromellose
Crospovidone type A
Lactose anhydrous

Pack sizes and marketing

Aluminium/polyamide/aluminium/PVC perforated unit-dose blister containing 10 × 1 tablets.

Votubia 2.5 mg tablets:

Packs containing 10 × 1, 30 × 1 or 100 × 1 tablets.

Votubia 5 mg tablets:

Packs containing 30 × 1 or 100 × 1 tablets.

Votubia 10 mg tablets:

Packs containing 10 × 1, 30 × 1 or 100 × 1 tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Marketing authorization dates and numbers

Votubia 2.5 mg tablets:

EU/1/11/710/001-003

Votubia 5 mg tablets:

EU/1/11/710/004-005

Votubia 10 mg tablets:

EU/1/11/710/006-008

Date of first authorisation: 02 September 2011
Date of latest renewal: 23 July 2020

Drugs

Drug Countries
VOTUBIA Austria, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.